Cover Image

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review

Show other versions (1)

Cisplatin has a pivotal role in the treatment of non-small cell lung cancer (NSCLC). However, it is associated with a number of serious and unpleasant side effects (nausea-vomiting, myelo-suppression, neuro-toxicity and renal function impairment). To overcome these limitations, most clinicians have...

Full description

Saved in:

Bibliographic Details
Main Authors:	Marcello Tiseo (Author), Andrea Ardizzoni (Author)
Format:	Book
Published:	Frontiers Media S.A., 2011-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
by: Ding Q, et al.
Published: (2013)

Chemotherapy in the treatment of thymic tumors
by: Marcello Tiseo, et al.
Published: (2011)

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
by: M Tiseo, et al.
Published: (2010)

Non-small-cell lung cancer: how to manage BRAF-mutated disease
by: Giorgia Guaitoli, et al.
Published: (2023)

Atezolizumab plus carboplatin and nab‐paclitaxel versus carboplatin and nab‐paclitaxel as treatments for Chinese, treatment‐naïve, stage IV, non‐squamous, non‐small‐cell lung cancer patients: A retrospective analysis
by: Yingkai Chen, et al.
Published: (2022)

Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung Cancer: A European Perspective
by: Umberto Malapelle, et al.
Published: (2021)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
by: Facchinetti F, et al.
Published: (2018)

Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe
by: Kui Huang, et al.
Published: (2020)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
by: Benjamin K. Schneider, et al.
Published: (2019)

Perftoran® Inhibits Hypoxia-Associated Resistance in Lung Cancer Cells to Carboplatin
by: Amira M. Gamal-Eldeen, et al.
Published: (2022)

Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2
by: Bin Ke, et al.
Published: (2019)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
by: Gridelli C, et al.
Published: (2018)

Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach
by: Francesca Di Pressa, et al.
Published: (2024)

Chemotherapy for small cell lung cancer: a comprehensive review
by: Syed Mustafa Karim, et al.
Published: (2012)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Sintilimab for the treatment of non-small cell lung cancer
by: Lin Zhang, et al.
Published: (2022)

Induction of ferroptosis by natural products in non-small cell lung cancer: a comprehensive systematic review
by: Qiang Zhang, et al.
Published: (2024)

MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
by: Longqiu Wu, et al.
Published: (2022)

Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients
by: Zulfan Zazuli, et al.
Published: (2020)

Development and Evaluation of a Quantitative Systems Pharmacology Model for Mechanism Interpretation and Efficacy Prediction of Atezolizumab in Combination with Carboplatin and Nab-Paclitaxel in Patients with Non-Small-Cell Lung Cancer
by: Chen-Yu Wang, et al.
Published: (2024)

Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation
by: Chao Zhang, et al.
Published: (2019)

Elevated N-Glycosylation Contributes to the Cisplatin Resistance of Non-Small Cell Lung Cancer Cells Revealed by Membrane Proteomic and Glycoproteomic Analysis
by: Wenjuan Zeng, et al.
Published: (2021)

Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance
by: Meng-Ran Wang, et al.
Published: (2020)

A comprehensive review on Brigatinib - A wonder drug for targeted cancer therapy in non-small cell lung cancer
by: Silky Bedi, et al.
Published: (2018)

Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer
by: Shanthi Ganesh, et al.
Published: (2013)

Survival and Side Effects of Cisplatin/Cyclophosphamide and Carboplatin/Paclitaxel Adjuvant Chemotherapy in Stage IC-IV Ovarian Cancer
by: Unedo H Markus, et al.
Published: (2015)

Nano-scale drug delivery systems for carboplatin: A comprehensive review
by: Mehrab Pourmadadi, et al.
Published: (2023)

Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland
by: Xiaoting Liu, et al.
Published: (2024)

Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis
by: Liangtao Wen, et al.
Published: (2023)

Maintenance therapy with oral etoposide following first-line docetaxel-cisplatin chemotherapy in metastatic non-small cell lung cancer patients
by: Meiyu Fang, et al.
Published: (2012)

A Multidimensional Bayesian Network Meta-Analysis of Chinese Herbal Injections for Treating Non-small Cell Lung Cancer With Gemcitabine and Cisplatin
by: Mengwei Ni, et al.
Published: (2021)

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
by: Pietro Carotenuto, et al.
Published: (2011)

Initial Systemic Treatment of Advanced Non-small Cell Lung Cancer
by: Muhammad Kamran Siddique, et al.
Published: (2019)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
by: Chao-Yue Sun, et al.
Published: (2018)

Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review
by: Kinga Ruszel, et al.
Published: (2020)

Treatment Results of Extracranial Malignant Germ Cell Tumor with Regimens of Cisplatin, Vinblastine, Bleomycin or Carboplatin, Etoposide, and Bleomycin with Special Emphasis on the Sites of Vagina and Testis
by: Jen-Yin Hou, et al.
Published: (2015)

Chemoresistance factors in non-small cell lung cancer
by: А. I. Shevchenko, et al.
Published: (2016)

Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
Published: (2021)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
by: Chien C-R, et al.
Published: (2012)